|   From the Trenches

From Poisons To Pills: Peptides

When a taxi driver finds out the name of my company, I am inevitably asked, “What does Bicycle Therapeutics do?” It’s not a question that came up when I worked at Trevena. My taxi driver would move straight on to discussing the weather or soccer or the news of the day. However, the word ‘Bicycle’ makes my world seemingly accessible to life beyond the biotech bubble.

This blog was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC.

Read more.


  |   LifeSciVC

Helping Others Conquer The Mountain

By Bruce Booth, DPhil, Partner

Snow sports are a passion of mine; almost any day up on a mountain is a great day. By combining this passion with a bigger purpose, I’ve recently tapped into a true vein of inspiration, integrating both my professional and personal life in a wonderful, unexpected way.

Read more.


  |   News

Atlas Venture Announces Two M&A Transactions

Two Atlas Venture portfolio companies announced significant deals to kick off 2017: Delinia was acquired by Celgene, and LTI signed an option-M&A deal with Allergan.

See the announcement.


  |   LifeSciVC

Seven Important Policy Agenda Items For BioPharma

By Bruce Booth, DPhil, Partner

President Trump’s tenure as the 45th POTUS has begun with even more fireworks than most pundits predicted – protests, marches, bans, and lots of other drama. The coastal Twitter/Facebook bubbles are exploding with anger and rage, while the Trump populists in the “other” America are celebrating. Seems like the country has gone crazy.

Read more.


  |   From the Trenches

Talent In The Biotech Gig Economy

Walking the streets of Union Square in mid-January torrential rain, we had the good fortune of sharing the Nimbus story with a number of investors, bankers, and pharma types. All of them were keen to hear what Nimbus was up to next, but some were surprised to hear that Nimbus was still around, as many thought our whole company was bought by Gilead ($GILD) last year. It wasn’t, and here is more on the why / how.

This blog was written by Jeb Keiper, CBO of Nimbus Therapeutics LLC, as part of the From The Trenches feature of LifeSciVC.

Read more.